Skip to main content
50°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Altimmune Inc
(NQ:
ALT
)
6.740
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Altimmune Inc
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
February 26, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
February 24, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
February 22, 2024
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.
Via
InvestorPlace
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
February 20, 2024
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
(ALT) - Analyzing Altimmune's Short Interest
February 14, 2024
Via
Benzinga
How Is The Market Feeling About Altimmune?
January 26, 2024
Via
Benzinga
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation - ALT
February 20, 2024
WHY: NEW YORK, NY - (NewMediaWire) - February 20, 2024 - Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...
Via
TheNewswire.com
NATIONALLY RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
February 19, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
ROSEN, A TOP RANKED LAW FIRM, Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
February 14, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report
February 13, 2024
Kerrisdale Capital has released a short report, making clear why it is betting against ALT stock. Here's why Altimmune is likely in trouble.
Via
InvestorPlace
$1000 Invested In Altimmune 5 Years Ago Would Be Worth This Much Today
December 08, 2023
Via
Benzinga
Altimmune Stock Sinks As Kerrisdale Capital Announces Short Position: 'Obvious Dead End'
February 13, 2024
Altimmune shares are trading lower Tuesday after short-selling investment firm Kerrisdale Capital published a new research report on the stock and announced a short position
Via
Benzinga
Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 13, 2024
Shares of IPG Photonics Corporation (NASDAQ: IPGP) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued soft first-quarter guidance.
Via
Benzinga
Jim Cramer Calls Affirm 'A Winner,' But Not C3.ai: 'I Can't Recommend A Stock With No Earnings'
February 13, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Vertiv Holdings Co (NYSE: VRT) is "one of the great per
Via
Benzinga
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
January 25, 2024
The best weight-loss drug stocks firms improving the drugs or developing new, potentially superior weight-loss treatments.
Via
InvestorPlace
2 biotechs with promising weight-loss drugs coming
January 16, 2024
Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co.
Via
MarketBeat
Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance
January 11, 2024
Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselves to tap into the
Via
Benzinga
The 3 Best Biotech Stocks to Buy in January 2024
January 09, 2024
Biotech is still one of the most exciting investments on the market, creating substantial opportunities for some of the best biotech stocks.
Via
InvestorPlace
Harpoon Therapeutics, Heron Therapeutics And Other Big Stocks Moving Higher In Monday's Pre-Market Session
January 08, 2024
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 150 points on Monday. Shares of Harpoon Therapeutics, Inc.(NASDAQ: HARP) rose sharply in pre-market trading....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
What's Going On With Obesity Drug-Developer Altimmune Inc Stock?
January 04, 2024
Altimmune, Inc. (NASDAQ: ALT) shares are trading higher Thursday, and the stock has gained more than 140% over the past month.
Via
Benzinga
Weight Watchers gains from Oprah’s GLP-1 weight-loss
January 02, 2024
Oprah Winfrey revealed she has lost over 60 pounds and is on the path to reaching her weight goal of 167 lbs. She credits this to taking GLP-1 medication
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
December 29, 2023
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.
Via
MarketBeat
Coherus BioSciences And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
December 27, 2023
U.S. stock futures were slightly lower this morning, with the Dow Jones futures falling around 5 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Gracell Biotechnologies, Stratasys, Hollysys Automation Technologies And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
December 26, 2023
U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 40 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December
December 19, 2023
Amidst fanfare for Nasdaq 100, U.S. small-cap stocks rally, with Russell 2000 index reaching levels not seen since Aug. 2022, 80% of stocks trading above 50-day MA, outperforming large caps &...
Via
Benzinga
Topics
ETFs
MarketBeat Week in Review: 12/11 - 12/15
December 16, 2023
The rally in stocks moved into high gear on hopes for interest rate hikes next year; conditions are right for the rally to continue into 2024.
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Can Altimmune's weight-loss drug be a game-changer?
December 14, 2023
The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold
Via
MarketBeat
Exposures
Product Safety
Bernie Sanders To Take On Ozempic, Wegovy, Weight Loss Drugs: 'Could Be Helpful, But They're Not Going To Be Helpful If People Can't Afford Them'
December 08, 2023
A hearing from the Senate led by Bernie Sanders will look at diabetes and the rise of weight loss drugs.
Via
Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
December 08, 2023
A weekly look at top trending tickers seeing increased attention from Benzinga users.
Via
Benzinga
Why Methode Electronics Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
December 07, 2023
Shares of Methode Electronics, Inc (NYSE: MEI) fell sharply during Thursday’s session following weak quarterly earnings.
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.